Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CMA1 | P23946 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | CDK4 | P11802 | 4/20 | 0.36 |
| ▸ | CCND1 | P24385 | 4/20 | 0.36 |
| ▸ | CCNE2 | O96020 | 3/20 | 0.36 |
| ▸ | CCNE1 | P24864 | 3/20 | 0.36 |
| ▸ | CDK2 | P24941 | 3/20 | 0.36 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.35 |
| ▸ | ICMT | O60725 | 1/20 | 0.35 |
| ▸ | OXER1 | Q8TDS5 | 1/20 | 0.35 |
| ▸ | PRKACA | P17612 | 1/20 | 0.35 |
| ▸ | PRKACG | P22612 | 1/20 | 0.35 |
| ▸ | PRKACB | P22694 | 1/20 | 0.35 |
| ▸ | CAMK2B | Q13554 | 1/20 | 0.35 |
| ▸ | CAMK2G | Q13555 | 1/20 | 0.35 |
| ▸ | CAMK2D | Q13557 | 1/20 | 0.35 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11005480 | 0.79 | CMA1 (0.48) | CMA1CDK4CCND1CCNE2CCNE1 | |
| SCHEMBL28919591 | 0.79 | CMA1 (0.44) | CMA1SMN1; SMN2TDP1 | |
| SCHEMBL689243 | 0.78 | CMA1 (0.47) | CMA1CDK4CCND1CCNE2CCNE1 | |
| SCHEMBL3132206 | 0.78 | CMA1 (0.44) | CMA1CDK4CCND1CCNE2CCNE1 | |
| SCHEMBL3670913 | 0.76 | CMA1 (0.60) | CMA1CDK4CCND1CCNE2CCNE1 | |
| Hydrochloric Acid SCHEMBL26107888 | 0.76 | CMA1 (0.43) | CMA1CDK4CCND1CCNE2CCNE1 | |
| SCHEMBL2259757 | 0.75 | ICMT (0.48) | LMNAICMTGAANPSR1 | |
| SCHEMBL30006444 | 0.75 | LGMN (0.38) | ICMTHTT | |
| SCHEMBL9275405 | 0.75 | PARP1 (0.44) | CMA1GAAADRA1DADRA1AADRA1B | |
| SCHEMBL30082247 | 0.75 | PARP1 (0.44) | CMA1GAAADRA1DADRA1AADRA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7109229-B2 | Methods and compounds for treating proliferative diseases | ELI LILLY AND COMPANY (US) | 2006-09-19 | — | — | US | disclosed |
| EP-1325011-B1 | METHODS AND COMPOUNDS FOR TREATING PROLIFERATIVE DISEASES | LILLY CO ELI (US) | 2004-05-06 | — | — | EP | disclosed |
| US-20040048915-A1 | Methods and compounds for treating proliferative diseases | ENGLER THOMAS ALBERT (US) | 2004-03-11 | — | — | US | disclosed |
| EP-1325011-A2 | METHODS AND COMPOUNDS FOR TREATING PROLIFERATIVE DISEASES | ELI LILLY AND COMPANY (US) | 2003-07-09 | — | — | EP | disclosed |
| WO-2002028861-A2 | METHODS AND COMPOUNDS FOR TREATING PROLIFERATIVE DISEASES | ELI LILLY AND COMPANY (US) | 2002-04-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040048915-A1 | Methods and compounds for treating proliferative diseases | CDK4, CCNI, CCNA1 | CMA1 2686/4885LMNA 1198/4885CDK4 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.